retatrutide eli lilly press release 2024 2025 https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-most-prescribed-weight-management “Eli and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound ADA '26: Lilly's dominance, Pfizer's

There is no evidence of serotonin syndrome, QT prolongation, or other serious drug interactions between these agents, but vigilance for additive side effects remains prudent

application of a 2 Hz train-of-four stimulus protocol using an nerve stimulator over the ulnar nerve) can be used to assist in patient management

Food restriction was maintained for 3 additional hours, at which point blood was sampled by submandibular vein bleeding

Delayed gastric emptying: As a class effect, incretin agents slow gastric emptying, which may affect the absorption of orally administered medicines

Girish A, Sekhon U, Sen Gupta A